230 related articles for article (PubMed ID: 34644155)
21. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
22. ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
Yang H; Huebner K; Hampel C; Erlenbach-Wuensch K; Selvamani SB; Shukla V; Geppert CI; Hartmann A; Mahadevan V; Schneider-Stock R
BMC Cancer; 2023 May; 23(1):480. PubMed ID: 37237279
[TBL] [Abstract][Full Text] [Related]
23. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
[TBL] [Abstract][Full Text] [Related]
24. Replication Stress Induces ATR/CHK1-Dependent Nonrandom Segregation of Damaged Chromosomes.
Xing M; Zhang F; Liao H; Chen S; Che L; Wang X; Bao Z; Ji F; Chen G; Zhang H; Li W; Chen Z; Liu Y; Hickson ID; Shen H; Ying S
Mol Cell; 2020 May; 78(4):714-724.e5. PubMed ID: 32353258
[TBL] [Abstract][Full Text] [Related]
25. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
26. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
27. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
[TBL] [Abstract][Full Text] [Related]
29. The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork.
Saldanha J; Rageul J; Patel JA; Kim H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445667
[TBL] [Abstract][Full Text] [Related]
30. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
32. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint.
Fukumoto Y; Morii M; Miura T; Kubota S; Ishibashi K; Honda T; Okamoto A; Yamaguchi N; Iwama A; Nakayama Y; Yamaguchi N
J Biol Chem; 2014 May; 289(18):12313-29. PubMed ID: 24634213
[TBL] [Abstract][Full Text] [Related]
33. Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D; Georganta A; Panagiotou E; Syrigos K; Souliotis VL
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474014
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
Liu K; Graves JD; Lin FT; Lin WC
J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
[TBL] [Abstract][Full Text] [Related]
35. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
36. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
Xiao G; Kue P; Bhosle R; Bargonetti J
Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
38. Critical role of SMG7 in activation of the ATR-CHK1 axis in response to genotoxic stress.
Ho K; Luo H; Zhu W; Tang Y
Sci Rep; 2021 Apr; 11(1):7502. PubMed ID: 33820915
[TBL] [Abstract][Full Text] [Related]
39. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
40. Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells.
Mordasini V; Ueda S; Aslandogmus R; Berger C; Gysin C; Hühn D; Sartori AA; Bernasconi M; Nadal D
Oncotarget; 2017 Jan; 8(4):6461-6474. PubMed ID: 28031537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
